BioForce Nanosciences Holdings (BFNH) Stock Statistics & Valuation Metrics
Total Valuation
BioForce Nanosciences Holdings has a market cap or net worth of $229.81M. The enterprise value is $59.71T.
- Market Cap
- $229.81M
- Enterprise Value
- $59.71T
Share Statistics
BioForce Nanosciences Holdings has 33,549,004 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 33,549,004
- Owned by Insiders
- 3.68%
- Owned by Institutions
- ―
Financial Efficiency
BioForce Nanosciences Holdings’s return on equity (ROE) is 2.09 and return on invested capital (ROIC) is 79.21%.
- Return on Equity (ROE)
- 2.09
- Return on Assets (ROA)
- -1643.70
- Return on Invested Capital (ROIC)
- 79.21%
- Return on Capital Employed (ROCE)
- 0.79
- Revenue Per Employee
- 0
- Profits Per Employee
- -430.65K
- Employee Count
- 3
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of BioForce Nanosciences Holdings is -2086.67. BioForce Nanosciences Holdings’s PEG ratio is -10.19.
- PE Ratio
- -2086.67
- PS Ratio
- 0.00
- PB Ratio
- 91.17
- Price to FCF
- -4981.30
- Price to Operating Cash Flow
- -4980.59
- PEG Ratio
- -10.19
Income Statement
In the last 12 months, BioForce Nanosciences Holdings had revenue of 0 and earned -1.29M in profits. Earnings per share was -0.04.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -489.95K
- Pretax Income
- -489.95K
- Net Income
- -1.29M
- EBITDA
- -489.95K
- Earnings Per Share (EPS)
- -0.04
Cash Flow
In the last 12 months, operating cash flow was -42.16K and capital expenditures 0, giving a free cash flow of -42.16K billion.
- Operating Cash Flow
- -42.16K
- Free Cash Flow
- -42.16K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
BioForce Nanosciences Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.02%
- Earnings Yield
- -0.05%
Stock Price Statistics
- Beta
- -0.17
- 52-Week Price Change
- 908.65%
- 50-Day Moving Average
- 7.46
- 200-Day Moving Average
- 2.70
- Relative Strength Index (RSI)
- 45.53
- Average Volume (3m)
- 11.37K
Financial Position
BioForce Nanosciences Holdings as a current ratio of 0.00, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.00
- Quick Ratio
- 0.00
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.00
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, BioForce Nanosciences Holdings has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
BioForce Nanosciences Holdings EV to EBITDA ratio is -342.17, with an EV/FCF ratio of -4981.30.
- EV to Sales
- 0.00
- EV to EBITDA
- -342.17
- EV to Free Cash Flow
- -4981.30
- EV to Operating Cash Flow
- -4981.30
Balance Sheet
BioForce Nanosciences Holdings has $307.00 in cash and marketable securities with $0.00 in debt, giving a net cash position of $307.00 billion.
- Cash & Marketable Securities
- $307.00
- Total Debt
- $0.00
- Net Cash
- $307.00
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- $0.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for BioForce Nanosciences Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 92.93%
Scores
- Smart Score
- 4
- AI Score
- ―
